ReviewLife (Basel, Switzerland)2023
Glaucoma and Systemic Disease.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Predictive value of peripheral blood lymphocytes for glaucoma susceptibility: a clinical observational study.BMC ophthalmology · 2026Observational
- Functional crosstalk between the lung and eye: a new frontier in chronic lung diseases.Archives of toxicology · 2025Review
- Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Multimodal Assessment of Ocular Parameters in Patients with Severe Obstructive Sleep Apnea with Emphasis on Retinal Structural Changes.Life (Basel, Switzerland) · 2025Article
- Sleep duration modifies the association between obstructive sleep apnea risk and glaucoma: evidence from the Korea National Health and Nutrition Examination Survey.Eye and vision (London, England) · 2025Article
- Uptake and Release Kinetics Longevity in Stimuli-Responsive Hydrogels for Hydrophilic Drug Therapy.ACS omega · 2025Article
- Lung Function as a Biomarker for Glaucoma: The UK Biobank Study.Investigative ophthalmology & visual science · 2025Article
- From tumor microenvironment to ocular hypertension: unraveling the pathogenesis and therapeutic strategies of cancer-related glaucoma.Frontiers in medicine · 2025Review
- Unveiling the silent link: Normal-tension glaucoma's enigmatic bond with cardiac blood flow.World journal of cardiology · 2024Review
- Ocular manifestations for misdiagnosing acute angle closure secondary to lens subluxation.Frontiers in medicine · 2024Article
- Review
- Glaucoma Characteristics and Influencing Factors during the COVID-19 Pandemic in the Huizhou Region.Journal of ophthalmology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is the leading cause of irreversible blindness in the world. Due to its potential to cause permanent vision loss, it is important to understand how systemic conditions and their respective treatments can be associated with or increase the risk for developing glaucoma. In this review, we examined the literature for up-to-date discussions and provided commentary on glaucoma, its pathophysiology, and associated risk factors. We discuss systemic diseases and the impact, risk, and mechanism for developing glaucoma, including pharmacologically induced glaucoma; inflammatory and auto-immune conditions; infectious, dermatologic, cardiovascular, pulmonary, renal, urologic, neurologic, psychiatric and systemic malignancies: intraocular tumors; as well as pediatric, and genetic conditions. The goal of our discussion of systemic conditions including their commonality, mechanisms, treatments, and associations with developing glaucoma is to emphasize the importance of ocular examinations and follow-up with the multidisciplinary teams involved in the care of each patient to prevent unnecessary vision-loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.